In brief: Avantogen, Novogen, Peplin, ResMed

Alastair Hood has resigned as a director of Avantogen (ASX:ACU), formerly Australian Cancer Technology, citing increased corporate and travel commitments with his investment company Bluespire as the reason for his departure.

Dr Graham Kelly has resigned as a director of Novogen (ASX:NRT) to focus on the development and expansion of its US subsidiary companies Glycotex and Marshall Edwards.

Former Queensland premier Wayne Goss will retire as a non-executive director of Peplin (ASX:PEP) at the company's annual general meeting. He was appointed as Deloitte Touche Tohmatsu's national chairman in June and is retiring as a Peplin director due to increased work commitments.

ResMed (ASX:RMD) has appointed US-based MediaFLO's CEO and president Richard Sulpizio as a director, replacing Christopher Bartlett, Professor Emertius of business administration at Harvard Business School.